Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial to Optimize the Dose of an Anti-NKG2A Monoclonal Antibody (humZ270 MAb, IPH2201) for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Haploidentical Transplantation with Post- Transplantation Cyclophosphamide

NCT06892223 is registered in ClinicalTrials.gov with Istituto Clinico Humanitas as lead sponsor.

NCT NCT06892223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06892223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial to Optimize the Dose of an Anti-NKG2A Monoclonal Antibody (humZ270 MAb, IPH2201) for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Haploidentical Transplantation with Post- Transplantation Cyclophosphamide
Lead sponsor
Istituto Clinico Humanitas
Phase
Phase 2
Overall status
Recruiting
Start date
December 3, 2021
Completion date
December 31, 2026
Enrollment
42 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukaemia, mds (myelodysplastic syndrome), mpn (myeloproliferative neoplasms)